Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Consuming coffee, even decaf, could protect against non-alcoholic fatty liver disease (NAFLD), according to a mouse study.
Gilead’s experimental hepatitis C treatment for all genotypes boasted a high success rate among those treated for the first time.
Researchers are launching trials of a $300 generic hepatitis C regimen that could help expand treatment of the virus in poorer nations.
People who receive hepatitis C treatment from community-based treatment providers are cured at the same rate as those who see specialists.
Jeffrey Lazarus interviews experts from the European Liver Patients Association about the changing field of viral hepatitis
People with hepatitis C do just as well with a liver transplant that is infected with the virus as those receiving an uninfected organ.
Having resistance to a particular class of hepatitis C drugs does not affect the likelihood of a cure with AbbVie’s Viekira Pak.
Researchers have developed a new algorithm to predict who will benefit from intensive care unit treatment of end-stage liver disease.
AbbVie’s hepatitis C virus (HCV) regimen Viekira Pak boasted excellent safety and efficacy data in a large, ongoing, real-world trial.
Gilead’s tenofovir alafenamide (TAF) combats hepatitis B comparably to and is safer than Viread (tenofovir disoproxil fumarate, or TDF).
Jeffrey Lazarus talks here about the changes he has seen in the hepatitis field since the International Liver Congress in 2007.
Western European men who have sex with men who have HIV and are cured of hepatitis C virus are reinfected with HCV at a very high rate.
Research suggests that some people are taking hep C therapy for longer periods than they actually need.
People retreated for hepatitis C virus after a failed cure attempt have a very good chance of achieving a cure.
Highlights from the 2016 International Liver Congress
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.